XTL's Drug Trial Fails
November 18, 2008 at 12:37 PM EST
Shares of XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB) collapsed $2.09 to 14 cents after the company reported failed clinical trials for its drug treatment of diabetic neuropathic pain.
